CoChat

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Open access

The DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.

Abstract

Non-alcoholic fatty liver disease and steatohepatitis are highly associated with obesity and type 2 diabetes mellitus. Cotadutide, a glucagon-like protein-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonist, was shown to reduce blood glycaemia, body weight and hepatic steatosis in people with type 2 diabetes mellitus. Here, we demonstrate that the effects of cotadutide in reducing body weight and food intake and improving glucose control are predominantly mediated through Glp-1 signalling, whereas its action on the liver to reduce lipid content, drive glycogen flux and improve mitochondrial turnover and function are directly mediated through Gcg signalling. This was confirmed by the identification of phosphorylation sites on key lipogenic and glucose metabolism enzymes in liver of mice treated with cotadutide. Complementary metabolomic and transcriptomic analyses implicated lipogenic, fibrotic and inflammatory pathways, consistent with a unique therapeutic contribution of GCGR agonism by cotadutide in vivo. Notably, cotadutide also alleviated fibrosis to a greater extent than liraglutide or obeticholic acid, despite dose adjustment to achieve similar weight loss in two preclinical mouse models of NASH. Thus, cotadutide, via direct hepatic (GcgR) and extrahepatic (Glp-1R) effects, exerts multifactorial improvement in liver function and is a promising therapeutic option for the treatment of steatohepatitis. Currently, there is no approved treatment for NAFLD and NASH. Here, Boland et al. show that the GLP-1R and GCGR dual-agonist cotadutide reduces hepatic steatosis, inflammation and fibrosis via GCGR agonism, and glucose homeostasis and weight gain by activating GLP-1 signalling.

Overview

Integrity signals

Registry

Crossref · 10.1038/s42255-020-0209-6

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 61 references

Cited by

See all 273

Metadata

Authors
Boland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., Feigh, M., Veidal, S. S., Lantier, L., McGuinness, O. P., Grimsby, J., Rondinone, C. M., Jermutus, L., Larsen, M. R., Trevaskis, J. L., & Rhodes, C. J.
Affiliations
  • AstraZeneca (United States) (US)
  • University of Southern Denmark (DK)
  • AstraZeneca (United Kingdom) (GB)
  • Gubra (Denmark) (DK)
  • Vanderbilt University (US)
  • Gilead Sciences (United States) (US)
Corresponding author
Rhodes, Christopher J.
Venue
Nature Metabolism
Published
2020-05-21
Volume
2
Issue
5
Pages
413-431
ISSN
2522-5812 (ISSN-L)
OpenAlex
W3027852565
Cited by
270
References
63
Citations by year
2026: 36 · 2025: 53 · 2024: 52 · 2023: 49 · 2022: 40 · 2021: 34 · 2020: 6
FWCI
23.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK059637)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
cotadutide, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver fibrosis, GLP-1 receptor, glucagon receptor, dual agonist, mitochondrial function, lipogenesis, hepatic steatosis, glucose homeostasis, weight loss, liraglutide, obeticholic acid, liver inflammation, type 2 diabetes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Glycogen, Liver, Liver Cirrhosis, Male, Mitochondria, Peptides, Mice, Knockout, Proteomics, Lipogenesis, Mice, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. https://app.cochat.ai/papers/10.1038/s42255-020-0209-6
The paper
Boland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., Feigh, M., Veidal, S. S., Lantier, L., McGuinness, O. P., Grimsby, J., Rondinone, C. M., Jermutus, L., Larsen, M. R., Trevaskis, J. L., & Rhodes, C. J. (2020). Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. Nature Metabolism. https://doi.org/10.1038/s42255-020-0209-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.